Kiniksa Pharmaceuticals International, plc

NasdaqGS:KNSA Voorraadrapport

Marktkapitalisatie: US$1.6b

Kiniksa Pharmaceuticals International Beheer

Beheer criteriumcontroles 4/4

Kiniksa Pharmaceuticals International's CEO is Sanj Patel, appointed in Jul 2015, has a tenure of 9.33 years. total yearly compensation is $5.30M, comprised of 16.3% salary and 83.7% bonuses, including company stock and options. directly owns 2.38% of the company’s shares, worth $38.56M. The average tenure of the management team and the board of directors is 3.8 years and 7.3 years respectively.

Belangrijke informatie

Sanj Patel

Algemeen directeur

US$5.3m

Totale compensatie

Percentage CEO-salaris16.3%
Dienstverband CEO9.3yrs
Eigendom CEO2.4%
Management gemiddelde ambtstermijn3.8yrs
Gemiddelde ambtstermijn bestuur7.3yrs

Recente managementupdates

Recent updates

Kiniksa Pharmaceuticals: Looking In On A Developing Growth Story

Oct 07

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Aug 07
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat

Jul 24

Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Share Price Is Matching Sentiment Around Its Revenues

Jun 19
Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Share Price Is Matching Sentiment Around Its Revenues

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Apr 25
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape

Apr 24

Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates

Mar 01
Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates

We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn

Feb 28
We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn

The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet

Dec 18
The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet

We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow

Nov 10
We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow

Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel

Apr 18
Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel

Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings

Nov 10
Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings

Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%

Aug 04
Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%

Kiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidance

Aug 03

Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results

May 05
Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results

We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate

Mar 18
We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate

Kiniksa: Latest Earnings Beat Shows Light At The End Of The Tunnel

Nov 25

Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?

Nov 04
Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?

Kiniksa: Unexciting, Slow Growth Stock

Aug 13

We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate

Jul 31
We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate

Kiniksa outlines development path for mavrilimumab after FDA feedback

Jun 08

Kiniksa: A Look At Mavrilimumab

May 03

Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation

Apr 17
Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation

Analyse CEO-vergoeding

Hoe is Sanj Patel's beloning veranderd ten opzichte van Kiniksa Pharmaceuticals International's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$9m

Jun 30 2024n/an/a

-US$10m

Mar 31 2024n/an/a

US$9m

Dec 31 2023US$5mUS$864k

US$14m

Sep 30 2023n/an/a

-US$7m

Jun 30 2023n/an/a

US$231m

Mar 31 2023n/an/a

US$196m

Dec 31 2022US$6mUS$835k

US$183m

Sep 30 2022n/an/a

US$143m

Jun 30 2022n/an/a

-US$112m

Mar 31 2022n/an/a

-US$134m

Dec 31 2021US$7mUS$803k

-US$158m

Sep 30 2021n/an/a

-US$175m

Jun 30 2021n/an/a

-US$189m

Mar 31 2021n/an/a

-US$184m

Dec 31 2020US$5mUS$780k

-US$161m

Sep 30 2020n/an/a

-US$140m

Jun 30 2020n/an/a

-US$123m

Mar 31 2020n/an/a

-US$122m

Dec 31 2019US$5mUS$780k

-US$162m

Sep 30 2019n/an/a

-US$173m

Jun 30 2019n/an/a

-US$170m

Mar 31 2019n/an/a

-US$153m

Dec 31 2018US$7mUS$740k

-US$103m

Sep 30 2018n/an/a

-US$93m

Jun 30 2018n/an/a

-US$85m

Mar 31 2018n/an/a

-US$76m

Dec 31 2017US$1mUS$700k

-US$65m

Compensatie versus markt: Sanj's total compensation ($USD5.30M) is about average for companies of similar size in the US market ($USD5.64M).

Compensatie versus inkomsten: Sanj's compensation has been consistent with company performance over the past year.

CEO

Sanj Patel (55 yo)

9.3yrs

Tenure

US$5,297,067

Compensatie

Mr. Sanj K. Patel has been the Chief Executive Officer of Kiniksa Pharmaceuticals International, plc (formerly known as Kiniksa Pharmaceuticals, Ltd.) since July 2015. Before founding Kiniksa Pharmaceutica...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Sanj Patel
CEO & Chairman of the Board9.3yrsUS$5.30m2.38%
$ 38.6m
Eben Tessari
Senior VP & COO2.8yrsUS$1.75m0.15%
$ 2.5m
John Paolini
Senior VP & Chief Medical Officer8.3yrsUS$1.79m0.072%
$ 1.2m
Mark Ragosa
Senior VP & CFO3.9yrsgeen gegevens0.032%
$ 516.0k
Michael Megna
Chief Accounting Officer & Group VP of Finance4.8yrsgeen gegevens0.037%
$ 596.2k
Mei Jang
Senior Vice President of Technical Operations3.8yrsgeen gegevensgeen gegevens
Chad Morin
Senior VP & Chief Compliance Officer3.6yrsgeen gegevensgeen gegevens
Madelyn Zeylikman
SVP, General Counsel & Secretary3.8yrsgeen gegevensgeen gegevens
Carsten Boess
Executive Vice President of Corporate Affairsno datageen gegevensgeen gegevens
Martina Struck
Senior Vice President of Regulatory Affairs3.9yrsgeen gegevensgeen gegevens
Ross Moat
Senior VP & Chief Commercial Officer2.8yrsgeen gegevens0.030%
$ 488.4k
Joseph Pirrello
Chief Business Officerless than a yeargeen gegevensgeen gegevens

3.8yrs

Gemiddelde duur

51.5yo

Gemiddelde leeftijd

Ervaren management: KNSA's management team is considered experienced (3.8 years average tenure).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Sanj Patel
CEO & Chairman of the Board9.3yrsUS$5.30m2.38%
$ 38.6m
Kimberly Popovits
Independent Director6.8yrsUS$362.66k0.013%
$ 210.6k
Felix Baker
Lead Independent Director9.1yrsUS$411.06k0.040%
$ 642.4k
Thomas Malley
Independent Director7.9yrsUS$380.36k0.013%
$ 210.6k
Barry Quart
Independent Director9.1yrsUS$372.55k0.013%
$ 210.6k
Richard Levy
Independent Director5.7yrsUS$459.75k0.018%
$ 289.8k
G. Cole
Independent Director4.3yrsUS$365.36k0.013%
$ 210.6k
Stephen Biggar
Independent Director9.1yrsUS$371.96k0.012%
$ 196.5k
Robert Desnick
Chairman of Scientific Advisory Boardno datageen gegevens2.05%
$ 33.2m
Tracey McCain
Independent Director6.8yrsUS$365.36k0.013%
$ 210.6k
M. Boyd
Directorless than a yeargeen gegevensgeen gegevens

7.3yrs

Gemiddelde duur

55.5yo

Gemiddelde leeftijd

Ervaren bestuur: KNSA's board of directors are considered experienced (7.3 years average tenure).